Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis

BACKGROUND: Atezolizumab plus chemotherapy has been recommended as a first-line treatment option for patients with advanced non-small cell lung carcinoma (NSCLC) irrespective of programmed cell death-ligand 1 (PD-L1) expression. Currently, little is known about the efficacy and treatment-related adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dan-Ni, Lu, Wen-Qing, Yang, Bo-Wen, Zhang, Ling-Yun, Jin, Bo, Wang, Shuo, Che, Xiao-Fang, Li, Ce, Liu, Yun-Peng, Qu, Xiu-Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212861/
https://www.ncbi.nlm.nih.gov/pubmed/34149702
http://dx.doi.org/10.3389/fimmu.2021.666909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212861/
https://www.ncbi.nlm.nih.gov/pubmed/34149702
http://dx.doi.org/10.3389/fimmu.2021.666909

Ejemplares similares